Results 291 to 300 of about 15,765 (342)

Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles

Journal of Nanoscience and Nanotechnology, 2010
The worldwide commerce involving nanoparticles will soon reach $1 trillion and already we have more than 600 commercial products containing nanoparticles. Because nanoparticles are invisible and little is known about their toxicities, there has been concern about health effects in humans.
Raymond S H, Yang, Louis W, Chang, Chung Shi, Yang, Pinpin, Lin   +3 more
openaire   +2 more sources

Physiologically-based pharmacokinetic model for 2,4-dinitrophenol

Journal of Pharmacokinetics and Pharmacodynamics, 2022
New approaches in drug development are needed to address the growing epidemic of obesity as the prevalence of obesity increases worldwide. 2,4-Dinitrophenol (DNP) is an oxidative phosphorylation uncoupling agent that was widely used in the early 1930s for weight loss but was quickly banned by the FDA due to the severe toxicities associated with the ...
Lyndsey F. Meyer, Pooja M. Rajadhyaksha, Dhaval K. Shah   +2 more
openaire   +2 more sources

Physiologically-Based Pharmacokinetic Modeling

Drug Information Journal, 1994
Physiologically-based pharmacokinetic (PB-PK) models attempt to provide both a realistic anatomic description of the animal to which a drug or toxic chemical has been administered and a biologically accurate representation of the physiological pathways for chemical storage, metabolism, and elimination in the animal.
openaire   +1 more source

Physiologically based pharmacokinetic modelling

2003
AbstractThis chapter provides a general introduction to physiologically based pharmacokinetic (PBPK) modeling of exposure in occupational and environmental epidemiological studies. It describes models that could be used for the assessment. It provides various examples and references.
George Loizou, Martin Spendiff
openaire   +1 more source

Whole-body physiologically based pharmacokinetic models

Expert Opinion on Drug Metabolism & Toxicology, 2007
This review summarizes the most recent developments in and applications of physiologically based pharmacokinetic (PBPK) modeling methodology originating from both the pharmaceutical and environmental toxicology areas. It focuses on works published in the last 5 years, although older seminal papers have also been referenced.
openaire   +2 more sources

Clearance Constants in Physiologically Based Pharmacokinetic Models

Journal of Pharmaceutical Sciences, 1979
The intrinsic clearance of an organ is usually approximated by the apparent clearance from that organ in the development of a physiologically based pharmacokinetic model. In this study, the exact relationship between the two clearances was derived and analyzed.
H S, Chen, J F, Gross
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling: Principles and Applications

Journal of Pharmaceutical Sciences, 1983
Concentrations of bromophenol blue (I) in plasma, urine, and bile were determined spectrophotometrically after intravenous bolus injections and infusions in rats. The plasma concentrations were found to decrease monoexponentially after all doses except the highest, where the decrease was biexponential.
L E, Gerlowski, R K, Jain
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling

2005
Preface. Acknowledgments. Contributors. Chapter 1. Introduction: A Historical Perspective of the Development and Applications of PBPK Models. 1. Introduction. 2. A Historical Perspective. 2-1. Responses to Inhaled Compounds. 2-2. Pharmaceutical Applications. 2-3. Occupational and Environmental Applications. 2-4. Digital Computation and PBPK Modeling. 3.
openaire   +1 more source

Sensitivity analysis for physiologically based pharmacokinetic models

Journal of Pharmacokinetics and Biopharmaceutics, 1991
The present study evaluates the sensitivity of pharmacokinetic model output to variability in the biochemical and metabolic input parameters. Pharmacokinetic models of three chemicals are chosen for analysis: styrene, methylchloroform, and methylene chloride.
D M, Hetrick, A M, Jarabek, C C, Travis
openaire   +2 more sources

Physiologically based pharmacokinetic model for vinylidene chloride

Toxicology and Applied Pharmacology, 1988
Vinylidene chloride (VDC), a potent hepatotoxin and suspected carcinogen, is metabolized by mixed-function oxidases into a reactive metabolite(s) which is responsible for its toxicity. The metabolite is detoxified by glutathione (GSH), and liver GSH status is an important factor in the expression of VDC toxicity. A physiologically based pharmacokinetic
R W, D'Souza, M E, Andersen
openaire   +2 more sources